Skip to main content
. 2018 Aug 1;10(3):110. doi: 10.3390/pharmaceutics10030110

Figure 4.

Figure 4

Cell viability of ARPE-19 cell lines exposed for 24 h to HA 0.15% and HA 0.30% formulations and commercial formulation (CR) containing 0.30% of hyaluronic acid (mean ± SD, n = 9). (* Significant statistical differences between both formulations p < 0.05).